Prevention of equine herpesvirus myeloencephalopathy – Is heparin a novel option? A case report.

This research investigates the potential use of heparin, a blood thinning compound, as a preventive measure during outbreaks of equine herpesvirus myeloencephalopathy (EHM), a severe horse illness. The study shows promising results with heparin-treated horses demonstrating a lower incidence rate of EHM in comparison to untreated horses during an outbreak.

Overview of EHM and the Need for Treatment

• The research revolves around a severe horse illness, EHM which results from the equine herpesvirus 1 (EHV-1) infection.
• Preventing and treating EHM during EHV-1 outbreaks is critical due to its severity, but there is currently no reliable and tested medication available for it.

The Hypothesis and the Treatment Procedure

• The researchers hypothesized that heparin, being a blood thinner, might be useful in reducing EHM incidence and severity since EHM has a thromboischemic (concerning blood clotting and decreased blood flow) nature and EHV-1 cell entry is blocked by heparin.
• During an acute EHV-1 outbreak with a specific neuropathogenic variant of the virus, metaphylactic (preventive) treatment with heparin was initiated as a test for this hypothesis.
• The article noted that clinical signs were present in 61 horses, from which 31 were treated by subcutaneous heparin injections twice daily for three days from the tenth day of the outbreak.

Treatment Analysis and Results

• The outcome of this treatment was then analyzed retrospectively, comparing the incidence of EHM in treated versus untreated horses.
• The incidence rate of EHM in the heparin-treated horses was substantially lower (3.2%) than in untreated horses (23.3%), substantiating the hypothesis that heparin could be beneficial in preventing EHM during an EHV-1 outbreak.

Conclusion and Future Research Directions

• While the results from this study are promising, they highlight the need for more comprehensive research in this area, due to the retrospective and non-randomized nature of the study.
• The paper suggests that future research should involve randomized and potentially blinded studies to further validate the effectiveness of heparin in preventing EHM during EHV-1 outbreaks.